Article

12-month results positive for laser presbyopia reversal

Laser presbyopia reversal (LAPR) is showing significant promise and patient satisfaction based on 12-month follow-up results from a U.S. clinical trial, said Sandra C. Belmont, MD, at the refractive surgery subspecialty day meeting.

New Orleans-Laser presbyopia reversal (LAPR) is showing significant promise and patient satisfaction based on 12-month follow-up results from a U.S. clinical trial, said Sandra C. Belmont, MD, at the refractive surgery subspecialty day meeting.

Dr. Belmont is a principal investigator in the two-center study that is being conducted at Weill Cornell Medical College, New York, and with Jon Siems, MD, at his private clinic in Las Vegas.

The procedure involves use of an erbium:YAG laser (OptiVision, SurgiLight) to create eight radial incisions in the sclera. The study enrolled 60 eyes of 30 patients with a mean age of 53 years (range 50-58). The eligibility criteria required patients to have accommodation (2.5 D, stable manifest refraction between -4.5 and +7.5 D, normal IOP, (0.75 D astigmatism, and no prior ophthalmic surgery.

Patients were able to read immediately after surgery, and at 12 months, the group demonstrated a statistically significant increase in near UCVA, with 90% achieving J3 or better. In addition, 100% of eyes had >1 D increased amplitude of accommodation with a mean increase of 2.4 D. One patient with a poor 12-month near vision outcome had resumed spectacle wear. Safety was favorable with no changes in IOP or corneal topography.

Other measurements showed the surgery resulted in an approximate 10-mm increase in circumferential diameter of the globe along with a statistically significant decrease in axial length and a statistically significant decrease in anterior chamber depth, which might reflect forward movement of the crystalline lens.

From the perspective of the surgeon, this procedure is easy to learn, although it takes about 45 minutes per eye, and so far, the patients are very happy, although it is important to make sure they do not return to wearing their glasses or they will lose the effect, Dr. Belmont said.

The trial is now being expanded to eight sites in the United States. LAPR is being performed in the Pacific Rim and recently received an approvability letter for the CE mark.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
© 2025 MJH Life Sciences

All rights reserved.